Skip to main content

Table 3 Toxicity after Celltop® and radiation

From: Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004–02

 

25 mg/day

50 mg/day

Mucositis

  

Grade 1/2

 

3

Grade 3

3

7

Radiodermitis

  

Grade 1/2

3

6

Grade 3

 

4

Dysphagia

  

Grade 1/2

3

6

Grade 3

 

4

Leucopenia

  

Grade 1/2

1

1

Grade 3/4

 

2

Neutropenia

  

Grade 1/2

 

1

Grade 3/4

 

2

Thrombopenia

  

Grade 1/2

 

1

Anemia

 

6

Grade 1/2

  

Renal

 

2

Grade 1

  
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us